Dr. Isabelle Bairati, MD, Ph.D., is a full professor in the Department of Surgery of the Faculty of Medicine at Laval University, a researcher at the CHU Research Centre of Quebec-Laval University (cancer axis), and a researcher at Laval University’s Cancer Research Centre. She carries out her medical activities as a medical consultant to the board of the Capitale-Nationale’s Public Health Department.
Since her postdoctoral training at the Fred Hutchinson Cancer Research Center in Seattle, USA, Dr. Bairati’s research activities have focused on epidemiology, and the clinical epidemiology of cancers. Her research has focused on the study of modifiable risk factors, including nutrition, on the occurrence of cancers, and their prognosis. More specifically, she was the principal investigator of a chemoprevention clinical trial, testing the effectiveness of antioxidant vitamins in preventing the occurrence of second primary cancers in patients with ENT cancer. This clinical trial has shown an adverse effect of high doses of antioxidants in patients with ENT cancer (J Natl Cancer Inst., 2005). During the last 10 years, her research has focused on the study of the prognostic effect of serum, tumor and genetic markers in ENT and ovarian cancers. As a public health physician, she is also interested in the impact of the organization of oncology health services on the prognosis and satisfaction of oncology clients.
6, rue McMahon
Canada G1R 2J6
Data not available
Factors Influencing the Prescription of Cardiovascular Preventive Therapies in Patients with Peripheral Arterial Disease.Journal Article
PLoS ONE, 11 (2), pp. e0148069, 2016.
A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways.Journal Article
Cancer Epidemiol, 42 , pp. 173-80, 2016, ISSN: 1877-7821.
Prognostic significance of TIMP-2, MMP-2, and MMP-9 on high-grade serous ovarian carcinoma using digital image analysis.Journal Article
Hum Pathol, 46 (5), pp. 739-45, 2015, ISSN: 0046-8177.
Dietary supplement use among cancer survivors of the NutriNet-Santé cohort study.Journal Article
Br J Nutr, 113 (8), pp. 1319-29, 2015, ISSN: 0007-1145.
Visual and automated assessment of matrix metalloproteinase-14 tissue expression for the evaluation of ovarian cancer prognosis.Journal Article
Mod Pathol, 27 (10), pp. 1394-404, 2014, ISSN: 0893-3952.
Development and validation of an instrument assessing women's satisfaction with screening mammography in an organized breast cancer screening program.Journal Article
BMC Health Serv Res, 14 , pp. 9, 2014.
A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.Journal Article
Gynecol Oncol, 131 (2), pp. 357-61, 2013, ISSN: 0090-8258.
Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients.Journal Article
Int J Cancer, 132 (11), pp. 2520-7, 2013, ISSN: 0020-7136.
Human epididymis protein 4 (HE4) and ovarian cancer prognosis.Journal Article
Gynecol Oncol, 127 (3), pp. 511-5, 2012, ISSN: 0090-8258.
Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies.Journal Article
Gynecol Oncol, 126 (3), pp. 491-8, 2012, ISSN: 0090-8258.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2022-06-13
- Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2021-12-31